Joe Biden is preparing to launch a groundbreaking initiative that will have a significant impact on the lives of everyday Americans. This initiative aims to lower the cost of prescription drugs for Medicare and its beneficiaries by negotiating directly with drug manufacturers. The process will begin with the announcement of the 10 drugs that will be subject to negotiation in the first year of the initiative. According to sources, this announcement will be made early this week, most likely on Tuesday morning.
While many economically advanced countries have long regulated drug prices through negotiation, the United States now has the opportunity to do the same for drugs in Medicare. However, it’s important to note that the newly discounted drugs won’t be available in the program until 2026. Nonetheless, this marks a significant change that has been years in the making, thanks to the Inflation Reduction Act signed by President Biden one year ago.
Supporters of this price negotiation process believe it will provide much-needed financial relief to those with high medical expenses while reducing the burden on taxpayers and premium-paying beneficiaries. Critics, on the other hand, argue that negotiation could hinder innovation by reducing financial rewards for drug companies.
Considering the contrasting views on negotiation, it’s crucial to focus on the first step of the process, which is the announcement of the initial 10 drugs. These drugs will be chosen based on their cost to Medicare and its beneficiaries. Analysts have made predictions on which drugs might be included in this list, such as Eliquis, which has the highest spending in Medicare Part D.
Following the announcement, negotiations will take place over the course of the next year, with the government collecting data, seeking public input, and exchanging price offers with manufacturers. If agreements cannot be reached, the government will make a final offer, and manufacturers will have the option to accept, refuse and face penalties, or withdraw from selling drugs to Medicare and other public programs altogether.
It’s important to note that the negotiated prices will not take effect until January 2026. This means it will be some time before Medicare beneficiaries see any savings from these negotiations. This lack of awareness about the reforms is reflected in a recent poll, which showed that only 25% of Americans are aware of the federal law authorizing price negotiation.
President Biden and his allies are using this week’s announcement as an opportunity to raise awareness about these reforms. By doing so, they hope to protect the reforms from future repeal efforts and gain public support, particularly in the upcoming 2024 elections. Price negotiation is an issue that garners high support across the political spectrum and has the potential to boost Biden’s approval ratings.
In conclusion, Joe Biden’s initiative to negotiate drug prices for Medicare represents a significant reform in the healthcare sector. While there are differing opinions on the impact of negotiation, the naming of the initial 10 drugs marks an important first step towards making prescription drugs more affordable for Americans.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
